SCHEMBL1664606

SCHEMBL1664606

CC(C)(C)OC(=O)N1CCC(c2nc(CC(F)(F)F)c[nH]2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.46
THRB P10828 2/20 0.46
MAPT P10636 1/20 0.46
HPGDS O60760 1/20 0.44
DPP4 P27487 1/20 0.43
DDB1 Q16531 1/20 0.43
CRBN Q96SW2 1/20 0.43
GPR119 Q8TDV5 2/20 0.41
IGF1R P08069 1/20 0.41
JAK1 P23458 2/20 0.41
JAK2 O60674 1/20 0.41
TYK2 P29597 1/20 0.41
JAK3 P52333 1/20 0.41
HTT P42858 1/20 0.41
TRPV3 Q8NET8 1/20 0.41
NAMPT P43490 1/20 0.41
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1662538 0.90 KDM4E (0.46) KDM4ETHRBMAPTHPGDSDPP4
SCHEMBL16457485 0.87 KDM4E (0.49) KDM4ETHRBMAPTHPGDSDPP4
SCHEMBL9894772 0.87 MAPT (0.46) KDM4ETHRBMAPTHPGDSDPP4
SCHEMBL16457261 0.86 KDM4E (0.48) KDM4ETHRBMAPTHPGDSDPP4
SCHEMBL27986654 0.86 KDM4E (0.48) KDM4ETHRBMAPTHPGDSDDB1
SCHEMBL16457442 0.84 THRB (0.49) KDM4ETHRBMAPTHPGDSDPP4
SCHEMBL16457551 0.84 KDM4E (0.49) KDM4ETHRBMAPTHPGDSDDB1
SCHEMBL1662413 0.83 KDM4E (0.49) KDM4ETHRBMAPTHPGDSDDB1
SCHEMBL1662364 0.81 KDM4E (0.42) KDM4ETHRBMAPTHPGDSDPP4
SCHEMBL2512441 0.81 KDM4E (0.52) KDM4ETHRBMAPTHPGDSDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2491032-B1 AKT INHIBITORS LILLY CO ELI (US) 2014-04-16 EP disclosed
EP-2491032-B1 AKT INHIBITORS LILLY CO ELI (US) 2014-04-16 EP disclosed
US-8436002-B2 AKT inhibitors ELI LILLY AND COMPANY (US) 2013-05-07 US disclosed
US-8436002-B2 AKT inhibitors ELI LILLY AND COMPANY (US) 2013-05-07 US disclosed
EP-2491032-A1 AKT INHIBITORS Eli Lilly and Company (US) 2012-08-29 EP disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed
US-20120149684-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2012-06-14 US disclosed
WO-2011050016-A1 AKT INHIBITORS ELI LILLY AND COMPANY (US) 2011-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149684-A1 AKT INHIBITORS AKT2, PIK3CA, AKT3 KDM4E 1851/4885THRB 2880/4885MAPT 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.